Drug intelligence / Profile preview

MW5031

Development stage: Preclinical
Lead developer: Shanghai Minwei Biotechnology
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

MW5031 is an investigational drug candidate being developed by Shanghai Minwei Biotechnology (also known as Minwei Biopharma). It is part of the company's pipeline focused on metabolic and endocrine diseases, utilizing their proprietary LAGMA (Long-Acting GLP-1-based Multi-Agonist) platform. While specific target details for MW5031 are not publicly disclosed in detail, the company specializes in multi-target agonists (dual, triple, and quadruple agonists) targeting receptors such as GLP-1R, GIPR, GCGR, and FGF21R for the treatment of conditions like Type 2 Diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). MW5031 is currently in clinical development.

Beyond the preview

Go deeper on MW5031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MW5031.

Explore the full profile